Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$162 Mln
Revenue (TTM)
$2 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.8
Industry P/E
--
EV/EBITDA
0.2
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
55,903,513
CFO
$-1,598.97 Mln
EBITDA
$-3,009.62 Mln
Net Profit
$-3,114.28 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Connect Biopharma Holdings (CNTB)
| -3.5 | 10.1 | -3.5 | 394.5 | 39.6 | -31.8 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Connect Biopharma Holdings (CNTB)
| 104.3 | 16.8 | 36.0 | -83.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Connect Biopharma Holdings (CNTB)
|
2.7 | 162.1 | 2.0 | -63.6 | -1,846.0 | -92 | -- | 2.8 |
| 62.9 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.6 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.0 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 91.2 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 7.1 | 6,847.2 | 113.3 | -351.4 | -211.0 | 71.1 | -- | 0.0 | |
| 529.8 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 489.5 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 319.3 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly... CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California. Address: 3580 CARMEL MOUNTAIN ROAD, San Diego, CA, United States, 92130 Read more
Co-Founder, President & Chairman of the Board of Directors
Dr. Wubin Pan M.B.A., Ph.D.
Co-Founder, President & Chairman of the Board of Directors
Dr. Wubin Pan M.B.A., Ph.D.
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Connect Biopharma Holdings Limited (CNTB) is $2.72 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Connect Biopharma Holdings Limited (CNTB) has given a return of 39.6% in the last 3 years.
Since, TTM earnings of Connect Biopharma Holdings Limited (CNTB) is negative, P/E ratio is not available.
The P/B ratio of Connect Biopharma Holdings Limited (CNTB) is 2.83 times as on 31-Mar-2026, a 28 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Connect Biopharma Holdings Limited (CNTB) are Rs 3.82 and Rs 0.51 as of 02-Apr-2026.
Connect Biopharma Holdings Limited (CNTB) has a market capitalisation of $ 162 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Connect Biopharma Holdings Limited (CNTB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.10
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.